Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Cash & Equivalents (2016 - 2026)

Orthopediatrics has reported Cash & Equivalents over the past 12 years, most recently at $12.2 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 63.54% year-over-year to $12.2 million; the TTM value through Mar 2026 reached $12.2 million, down 63.54%, while the annual FY2025 figure was $19.6 million, 55.37% down from the prior year.
  • Cash & Equivalents for Q1 2026 was $12.2 million at Orthopediatrics, down from $19.6 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $51.0 million in Q3 2024 and troughed at $9.0 million in Q4 2022.
  • A 5-year average of $26.4 million and a median of $25.3 million in 2024 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: tumbled 73.89% in 2023 and later surged 379.77% in 2024.
  • Year by year, Cash & Equivalents stood at $9.0 million in 2022, then skyrocketed by 245.4% to $31.1 million in 2023, then soared by 41.1% to $43.8 million in 2024, then crashed by 55.37% to $19.6 million in 2025, then plummeted by 37.65% to $12.2 million in 2026.
  • Business Quant data shows Cash & Equivalents for KIDS at $12.2 million in Q1 2026, $19.6 million in Q4 2025, and $16.8 million in Q3 2025.